Medicine
Assistant Professor
Lungpacer. “A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning from Mechanical Ventilation in ICU Patients.” RESCUE-3
a. Sub-investigator
Grifols Therapeutics LLC “A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Subjects with COVID-19 Requiring Admission to the Intensive Care Unit”
a. Sub-investigator
Incyte Corp. “An Open-Label Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Store from Covid –19 Infection.
a. Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID) 20-0006. “Randomized, double-blind, placebo-controlled to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. Adaptive COVID-19 Treatment Trial 4 (ACTT-4)”
a. Principal Investigator
InsMed INS-415: ARISE – A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
a. Sub-Investigator
InsMed INS-416: ENCORE – A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS) – Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
Galapagos GLPG1690-CL-303: “A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate efficacy and safety of two doses of GLPG1690 in addition to local standard of care for a minimum of 52 weeks in subjects with idiopathic pulmonary fibrosis”
a. Sub-investigator
The effects of Prophylactic scheduled Melatonin in Patients in the Intensive care unit in preventing ICU acquired Delirium
a. Sub-investigator
Novartis NCT04362137: “Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)”
a. Principal-Investigator
CF-301-105: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard of Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Right-Sided Endocarditis (2020- 2022)
Contrafect CF301-102: “A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability and Efficacy of CF-301 vs. Placebo in Addition to Standard of Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Endocarditis”
a. Sub-investigator
Mayo Clinic: “US Expanded Access Program for Convalescent Plasma for the Treatment of Patients with Covid-19
a. Local Principal-investigator
Novartis CQAW039A2315: “A 2-treatment period, randomized, placebo-controlled, multicenter, parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA Steps 3, 4, and 5 patients with uncontrolled asthma”
a. Sub-investigator
Roche CP40617: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination with Standard of Care Neuraminidase Inhibitor in Hospitalized Patients with Severe Influenza”
a. Sub-investigator
Boehringer Ingelheim 1305-0013: A randomized, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating the efficacy, safety and tolerability of BI 1015550 18 mg taken orally B.I.D.
a. Sub-Investigator
Shionogi 1713R2117: “An Open-label Study to Assess the Intrapulmonary Concentrations of Cefiderocol at Steady State in Hospitalized Subjects with Bacterial Pneumonia on Treatment with Standard of Care Antibiotics and requiring Mechanical Ventilation”
a. Sub-investigator
Takeda 2002: “A Phase 2b, Randomized, Multi-Center, Double-Blind Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 In Critically Ill Patients with Enteral Feeding Intolerance”
a. Sub-investigator
Merck MK-7264-030: “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough” (PN030)
a. Sub-investigator